Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Genmab A/S
GMAB
NASDAQ·Healthcare·Biotechnology·Mkt cap $17.0B
$28.52
▲ +3.17%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$20.23 - $35.43
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 35.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary antibody technology platform and manufacturing expertise
- Diversified portfolio with marketed blockbuster products and deep pipeline
- Strategic partnerships with major pharmaceutical companies (Janssen, AbbVie, Seagen)
- Strong intellectual property position and patent protection
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Strong growth ahead
Expanding DARZALEX and daratumumab market penetration in multiple indications
Value
Undervalued - trading well below Biotech & Therapeutics peers
Momentum
Stable
+0.5% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GMAB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 6, 2026
MAY 7, 2026
Reported EPS of $0.09 vs $0.15 consensus (-42.0% surprise). Revenue of $896.0M vs $905.8M expected (-1.1%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-42.0%
Next: Aug 6, 2026
Revenue trend · last 8Q
—
—
—
+19%
+652%
-82%
-84%
+26%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$120.9M
$859.9M
$999.7M
$111.0M
$909.8M
$158.6M
$163.7M
$139.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
5.9%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$39.00
▲ +36.8% vs $28.52
Latest: HC Wainwright · Jul 2, 2026
2 analysts covering